{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:22Z","timestamp":1791005782208,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10067-017-3712-8","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T11:37:45Z","timestamp":1496921865000},"page":"1747-1755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-6467","authenticated-orcid":false,"given":"Ennio Giulio","family":"Favalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Becciolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Biggioggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Crotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Gattinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gerloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"3712_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"3712_CR2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum dis 69:718\u2013722","journal-title":"Ann Rheum dis"},{"key":"3712_CR3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/art.20793","volume":"52","author":"V Gerloni","year":"2005","unstructured":"Gerloni V, Pontikaki I, Gattinara M et al (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 52:548\u2013553","journal-title":"Arthritis Rheum"},{"key":"3712_CR4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837\u2013846","journal-title":"Ann N Y Acad Sci"},{"key":"3712_CR5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00d8stergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382\u2013390","journal-title":"Arthritis Rheum"},{"key":"3712_CR6","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry. Ann Rheum dis 69:2002\u20132008","journal-title":"Ann Rheum dis"},{"key":"3712_CR7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie E, Kristensen LE, Forsblad-d\u2019Elia H et al (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum dis 74:970\u2013978","journal-title":"Ann Rheum dis"},{"key":"3712_CR8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde DM et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum dis 73:132\u2013137","journal-title":"Ann Rheum dis"},{"key":"3712_CR9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M et al (2016) Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care & Research 68:432\u2013439","journal-title":"Arthritis Care & Research"},{"key":"3712_CR10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","volume":"68","author":"P Tynjala","year":"2009","unstructured":"Tynjala P, Vahasalo P, Honkanen V et al (2009) Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum dis 68:552\u2013557","journal-title":"Ann Rheum dis"},{"key":"3712_CR11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","volume":"55","author":"AF Mour\u00e3o","year":"2016","unstructured":"Mour\u00e3o AF, Santos MJ, Melo Gomes JA et al (2016) Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology (Oxford) 55:697\u2013703","journal-title":"Rheumatology (Oxford)"},{"key":"3712_CR12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"3712_CR13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"SVD Linden","year":"1984","unstructured":"Linden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"3712_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55\u201378","journal-title":"Semin Arthritis Rheum"},{"key":"3712_CR15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","volume":"10","author":"Y-T Lin","year":"2011","unstructured":"Lin Y-T, Wang C-T, Gershwin ME et al (2011) The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun rev 10:482\u2013489","journal-title":"Autoimmun rev"},{"key":"3712_CR16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.berh.2009.08.003","volume":"23","author":"SJ Vastert","year":"2009","unstructured":"Vastert SJ, Kuis W, Grom AA (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract res Clin Rheumatol 23:655\u2013664","journal-title":"Best Pract res Clin Rheumatol"},{"key":"3712_CR17","doi-asserted-by":"publisher","unstructured":"Favalli EG, Selmi C, Becciolini A, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multi-center retrospective analysis. Arthritis Care Res 2016; Accepted Author Manuscript. doi:\n10.1002\/acr.23090","DOI":"10.1002\/acr.23090"},{"key":"3712_CR18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","volume":"70","author":"MM Soliman","year":"2011","unstructured":"Soliman MM, Ashcroft DM, Watson KD et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum dis 70:583\u2013589","journal-title":"Ann Rheum dis"},{"key":"3712_CR19","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, Gomez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72","journal-title":"Arthritis Res Ther"},{"key":"3712_CR20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Pan Du","year":"2009","unstructured":"Pan Du SM, Dehler S, Ciurea A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560\u2013568","journal-title":"Arthritis Rheum"},{"key":"3712_CR21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","volume":"50","author":"W Kievit","year":"2011","unstructured":"Kievit W, Fransen J, Adang EMM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50:196\u2013203","journal-title":"Rheumatology (Oxford)"},{"key":"3712_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","volume":"53","author":"JD Rosenblat","year":"2014","unstructured":"Rosenblat JD, Cha DS, Mansur RB et al (2014) Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 53:23\u201334","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3712_CR23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","volume":"67","author":"V Gerloni","year":"2008","unstructured":"Gerloni V, Pontikaki I, Gattinara M et al (2008) Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum dis 67:1145\u20131152","journal-title":"Ann Rheum dis"},{"key":"3712_CR24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrrheum.2015.20","volume":"11","author":"ES Sen","year":"2015","unstructured":"Sen ES, Dick AD, Ramanan AV (2015) Uveitis associated with juvenile idiopathic arthritis. Nat rev Rheumatol 11:338\u2013348","journal-title":"Nat rev Rheumatol"},{"key":"3712_CR25","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3899\/jrheum.140472","volume":"42","author":"D Barthel","year":"2015","unstructured":"Barthel D, Ganser G, Kuester R-M et al (2015) Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol 42:2160\u20132165","journal-title":"J Rheumatol"},{"key":"3712_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum dis 74:65\u201373","journal-title":"Ann Rheum dis"},{"key":"3712_CR27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/acr.22649","volume":"68","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Schenck S, Niewerth M et al (2016) Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care & Research 68:46\u201354","journal-title":"Arthritis Care & Research"},{"key":"3712_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12891-015-0489-2","volume":"16","author":"D Wu","year":"2015","unstructured":"Wu D, Guo Y-Y, Xu N-N et al (2015) Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord 16:19","journal-title":"BMC Musculoskelet Disord"},{"key":"3712_CR29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acr.22214","volume":"66","author":"G Simonini","year":"2014","unstructured":"Simonini G, Druce K, Cimaz R et al (2014) Current evidence of anti-tumor necrosis factor \u03b1 treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care & Research 66:1073\u20131084","journal-title":"Arthritis Care & Research"},{"key":"3712_CR30","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52:2447\u20132451","journal-title":"Arthritis Rheum"},{"key":"3712_CR31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11894-003-0040-8","volume":"5","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ (2003) Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol rep 5:501\u2013505","journal-title":"Curr Gastroenterol rep"},{"key":"3712_CR32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57:639\u2013647","journal-title":"Arthritis Rheum"},{"key":"3712_CR33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Xie F, Chen L et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773\u20132780","journal-title":"Arthritis Rheum"},{"key":"3712_CR34","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287\u20132293","journal-title":"Arthritis Rheum"},{"key":"3712_CR35","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403\u20133412","journal-title":"Arthritis Rheum"},{"key":"3712_CR36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"JD Greenberg","year":"2010","unstructured":"Greenberg JD, Reed G, Kremer JM et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum dis 69:380\u2013386","journal-title":"Ann Rheum dis"},{"key":"3712_CR37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:124\u2013131","journal-title":"Rheumatology (Oxford)"},{"key":"3712_CR38","unstructured":"Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with TNF-inhibitors and disease activity in the German BIKER registry. Arthritis care & research Published Online First: 7 July 2016."},{"key":"3712_CR39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692\u2013701","journal-title":"Arthritis Rheum"},{"key":"3712_CR40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","volume":"64","author":"BL Nordstrom","year":"2012","unstructured":"Nordstrom BL, Mines D, Gu Y et al (2012) Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care & Research 64:1357\u20131364","journal-title":"Arthritis Care & Research"},{"key":"3712_CR41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/art.38339","volume":"66","author":"K Hellgren","year":"2014","unstructured":"Hellgren K, Smedby KE, Backlin C et al (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66:1282\u20131290","journal-title":"Arthritis Rheumatol"},{"key":"3712_CR42","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/art.34349","volume":"64","author":"KB Onel","year":"2012","unstructured":"Onel KB, Onel K (2012) Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web. Arthritis Rheum 64:966\u2013969","journal-title":"Arthritis Rheum"},{"key":"3712_CR43","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295:2275\u20132285","journal-title":"Jama"},{"key":"3712_CR44","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","volume":"12","author":"A Strangfeld","year":"2010","unstructured":"Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis res Ther 12:R5","journal-title":"Arthritis res Ther"},{"issue":"6","key":"3712_CR45","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","volume":"74","author":"LK Mercer","year":"2015","unstructured":"Mercer LK, Lunt M, Low ALS, Dixon WG, Watson KD, Symmons DPM et al (2015) Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum dis 74(6):1087\u20131093","journal-title":"Ann Rheum dis"},{"key":"3712_CR46","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","volume":"64","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Haynes K, Curtis JR et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263\u20131271","journal-title":"Arthritis Rheum"},{"issue":"4 Suppl 78","key":"3712_CR47","first-page":"S22","volume":"31","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Hirata S, Saleem B, Emery P (2013) Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 31(4 Suppl 78):S22\u2013S27","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3712_CR48","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.22477","volume":"67","author":"CY Chang","year":"2015","unstructured":"Chang CY, Meyer RML, Reiff AO (2015) Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care res 67(5):658\u2013666","journal-title":"Arthritis Care res"},{"key":"3712_CR49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22\u201332","journal-title":"Arthritis Rheum"},{"key":"3712_CR50","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3899\/jrheum.111125","volume":"39","author":"F Iannone","year":"2012","unstructured":"Iannone F, Gremese E, Atzeni F et al (2012) Longterm retention of tumor necrosis factor-\u03b1 inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39:1179\u20131184. doi:\n10.3899\/jrheum.111125","journal-title":"J Rheumatol"},{"issue":"2","key":"3712_CR51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","volume":"55","author":"T Schaeverbeke","year":"2016","unstructured":"Schaeverbeke T, Truchetet M-E, Kostine M, Barnetche T, Bannwarth B, Richez C (2016) Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford) 55(2):210\u2013220","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3712-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T09:19:02Z","timestamp":1500542342000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3712"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3712-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}